NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, announced today that an abstract related to IO102-IO103, the company’s lead investigational therapeutic cancer vaccine candidate, has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2024. The poster will share data from one of the Phase 2 basket trials ...

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its Twin® platform, announced today that an abstract related to IO102-IO103, the company's lead investigational therapeutic cancer vaccine candidate, has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2024. The poster will share data from one of the Phase 2 basket trials o ...

Exhibit 99.1 IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights • Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with pembrolizumab still expected in Q3 2024; outcome of primary endpoint of progression free survival (PFS) is now projected to occur in first half of 2025 • Completed enrollment ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-41008 IO Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 87-0 ...

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced the acceptance of an abstract related to IO102-IO103, the company's lead investigational therapeutic cancer vaccine candidate, for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago May 31-June 4, 2024. A trial-in-progress poster from ...

NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Marjan Shamsaei, PharmD, joined the company as SVP, Commercial Development and Portfolio Lead for IO102-IO103, the company's lead cancer vaccine candidate currently in a pivotal Phase 3 trial. Ms. Shamsaei joins the company's executive team, reporting to IO Biotech CEO Mai-Britt Zoc ...

NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today shared new data related to the company's lead therapeutic cancer vaccine candidate, IO102-IO103, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, California. "These data build on earlier studies that demonstrated the mechanism ...

公司资格和披露要求 - 公司是一家“新兴增长型公司”，可以享受一些适用于其他非新兴增长型公司的豁免规定，包括提供两年审计财务报表，不需要遵守审计师对财务报告内部控制的要求等[320] - 公司将继续作为“新兴增长型公司”直至满足特定条件，包括首次公开募股五周年后的财政年度结束、年度总收入达到12.35亿美元或更多、在前三年内发行了10亿美元以上的非可转换债券等[322] - 公司是一家“小型报告公司”，市值由非关联方持有的股票少于7亿美元，最近完成的财政年度年度收入少于1亿美元。小型报告公司可以享受一些减少披露义务的优惠，包括在年度10-K报告中只提供两年审计财务报表[322] - 公司将继续作为小型报告公司，直至非关联方持有的普通股市值在年度第二季度结束时超过2.5亿美元且年度收入超过1亿美元，或者非关联方持有的普通股市值在年度第二季度结束时超过7亿美元[323] 监管合规和内部控制 - 公司作为公开公司，面临着日益严格的监管环境，需要遵守萨班斯-奥克斯法案、SEC的规定、Nasdaq的规则和规定等，这些要求包括建立公司监督和充分的内部控制以确保财务报告的可靠性[326] - 公司必须在2022年结束的财政年度开始对其财务报告的内部控制进行系统和流程评估和测试，以便管理履行在10-K表格中报告内部控制有效性的要求[327] 风险因素 - 公司将有广泛的自由裁量权来使用现有的现金及现金等价物，可能会对业务和财务状况产生不利影响[334] - 公司面临着来自黑客和数据窃贼的日益复杂和规模庞大的自动化攻击，可能在发生后仍未被察觉[336] - 全球经济和政治不稳定性以及俄乌冲突和中东冲突等冲突可能对公司业务、财务状况或运营结果产生不利影响[338] - 公司可能受到美国和外国司法管辖区内不稳定的经济和政治状况以及地缘政治冲突的不利影响[339] - 公司和与其共享设施的第三方受到许多环境、健康和安全法律法规的约束，违反这些法规可能导致巨额罚款、处罚或其他制裁[342] - 公司可能面临证券集体诉讼，这可能导致巨额成本和管理层注意力和资源的分散，从而损害公司业务[344] 市场和投资者关系 - 公司的普通股交易市场在一定程度上取决于证券或行业分析师对公司或业务的研究和报告[346] - 公司未来可能会受到来自投资者和利益相关者对环境、社会和公司治理（ESG）事项期望的影响，未能满足这些期望可能对公司声誉产生负面影响[347]

Exhibit 99.1 IO Biotech Announces 2023 Fourth-Quarter and Year-End Results • Completed enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma; planned interim analysis for overall response rate (ORR) expected in third quarter of 2024 by independent data monitoring committee • Progressed clinical development of IO102-IO103 with first patient dosed in Phase 2 basket trial of IO102-IO ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-41008 IO Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware ...